Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults

References

• Global Tuberculosis Control. WHO report 2011. Geneva: World Health Organisation, 2011.
   Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173 - 80; http://dx.doi.org/10.1016/S0140-6736(06)68507-3; PMID: 16616560
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698 - 702; http://dx.doi.org/10.1001/jama.1994.03510330076038; PMID: 8309034
   PubMed Web of Science ®Google Scholar
• Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82:193 - 6; PMID: 17526121
   PubMedGoogle Scholar
• Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 2004; 84:93 - 101; http://dx.doi.org/10.1016/j.tube.2003.08.010; PMID: 14670350
   PubMed Web of Science ®Google Scholar
• Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005; 174:449 - 55; PMID: 15611270
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012; 185:769 - 78; http://dx.doi.org/10.1164/rccm.201108-1548OC; PMID: 22281831
   PubMed Web of Science ®Google Scholar
• Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, Harris S, et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 2011; 1:e000223; http://dx.doi.org/10.1136/bmjopen-2011-000223; PMID: 22102640
   PubMed Web of Science ®Google Scholar
• Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, et al. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 2011; 3:88ra56; http://dx.doi.org/10.1126/scitranslmed.3002461; PMID: 21697532
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Mauff K, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 2011; 203:1832 - 43; http://dx.doi.org/10.1093/infdis/jir195; PMID: 21606542
   PubMed Web of Science ®Google Scholar
• Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, Alder N, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009; 179:724 - 33; http://dx.doi.org/10.1164/rccm.200809-1486OC; PMID: 19151191
   PubMed Web of Science ®Google Scholar
• Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, et al. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 2008; 3:e2921; http://dx.doi.org/10.1371/journal.pone.0002921; PMID: 18698342
   PubMed Web of Science ®Google Scholar
• Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008; 198:544 - 52; http://dx.doi.org/10.1086/590185; PMID: 18582195
   PubMed Web of Science ®Google Scholar
• Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, Asher TE, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007; 37:3089 - 100; http://dx.doi.org/10.1002/eji.200737504; PMID: 17948267
   PubMed Web of Science ®Google Scholar
• Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, et al. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One 2007; 2:e1052; http://dx.doi.org/10.1371/journal.pone.0001052; PMID: 17957238
   PubMedGoogle Scholar
• McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240 - 4; http://dx.doi.org/10.1038/nm1128; PMID: 15502839
   PubMed Web of Science ®Google Scholar
• Williams A, Goonetilleke NP, McShane H, Clark SO, Hatch G, Gilbert SC, et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 2005; 73:3814 - 6; http://dx.doi.org/10.1128/IAI.73.6.3814-3816.2005; PMID: 15908420
   PubMed Web of Science ®Google Scholar
• Walther M, Woodruff J, Edele F, Jeffries D, Tongren JE, King E, et al. Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol 2006; 177:5736 - 45; PMID: 17015763
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006; 24:3026 - 34; http://dx.doi.org/10.1016/j.vaccine.2005.10.058; PMID: 16488059
   PubMed Web of Science ®Google Scholar
• Rowland R, Brittain N, Poulton ID, Minassian AM, Sander C, Porter DW, et al. A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in Vaccinology 2012; 1:27 - 35; http://dx.doi.org/10.1016/j.trivac.2012.07.001
   Google Scholar
• Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, et al, NIAID HIV Vaccine Trials Network. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948 - 58; http://dx.doi.org/10.1016/j.vaccine.2010.12.104; PMID: 21216311
   PubMed Web of Science ®Google Scholar
• Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011; 29:7514 - 22; http://dx.doi.org/10.1016/j.vaccine.2011.03.083; PMID: 21501642
   PubMed Web of Science ®Google Scholar
• Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5:e13983; http://dx.doi.org/10.1371/journal.pone.0013983; PMID: 21085591
   PubMed Web of Science ®Google Scholar
• Guerra S, López-Fernández LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004; 78:5820 - 34; http://dx.doi.org/10.1128/JVI.78.11.5820-5834.2004; PMID: 15140980
   PubMed Web of Science ®Google Scholar
• Sawant KV, Cho H, Lyons M, Ly LH, McMurray DN. Guinea pig neutrophil-macrophage interactions during infection with Mycobacterium tuberculosis. Microbes Infect 2010; 12:828 - 37; http://dx.doi.org/10.1016/j.micinf.2010.05.009; PMID: 20685396
   PubMed Web of Science ®Google Scholar
• Sterling TR, Dorman SE, Chaisson RE, Ding L, Hackman J, Moore K, et al. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 2001; 33:976 - 82; http://dx.doi.org/10.1086/322670; PMID: 11528568
   PubMed Web of Science ®Google Scholar
• Tuberculosis. Green Book: Department of Health, 2011:403-7.
   Google Scholar
• Laidlaw SM, Skinner MA. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses. J Gen Virol 2004; 85:305 - 22; http://dx.doi.org/10.1099/vir.0.19568-0; PMID: 14769888
   PubMed Web of Science ®Google Scholar
• Qingzhong Y, Barrett T, Brown TD, Cook JK, Green P, Skinner MA, et al. Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F). Vaccine 1994; 12:569 - 73; http://dx.doi.org/10.1016/0264-410X(94)90319-0; PMID: 8036832
   PubMed Web of Science ®Google Scholar
• McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 2002; 70:1623 - 6; http://dx.doi.org/10.1128/IAI.70.3.1623-1626.2002; PMID: 11854254
   PubMed Web of Science ®Google Scholar
• Howles S, Guimarães-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, et al. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine 2010; 28:7306 - 12; http://dx.doi.org/10.1016/j.vaccine.2010.08.077; PMID: 20816902
   PubMed Web of Science ®Google Scholar
• Meyer VS, Kastenmuller W, Gasteiger G, Franz-Wachtel M, Lamkemeyer T, Rammensee HG, et al. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J Immunol 2008; 181:6371 - 83; PMID: 18941228
   PubMed Web of Science ®Google Scholar
• Strug I, Calvo-Calle JM, Green KM, Cruz J, Ennis FA, Evans JE, et al. Vaccinia peptides eluted from HLA-DR1 isolated from virus-infected cells are recognized by CD4+ T cells from a vaccinated donor. J Proteome Res 2008; 7:2703 - 11; http://dx.doi.org/10.1021/pr700780x; PMID: 18507432
   PubMed Web of Science ®Google Scholar
• Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog 2007; 3:1511 - 29; http://dx.doi.org/10.1371/journal.ppat.0030144; PMID: 17937498
   PubMed Web of Science ®Google Scholar
• Terajima M, Cruz J, Leporati AM, Demkowicz WE Jr., Kennedy JS, Ennis FA. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum Immunol 2006; 67:512 - 20; http://dx.doi.org/10.1016/j.humimm.2005.12.004; PMID: 16829305
   PubMed Web of Science ®Google Scholar
• Oseroff C, Kos F, Bui HH, Peters B, Pasquetto V, Glenn J, et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A 2005; 102:13980 - 5; http://dx.doi.org/10.1073/pnas.0506768102; PMID: 16172378
   PubMed Web of Science ®Google Scholar
• Drexler I, Staib C, Kastenmuller W, Stevanović S, Schmidt B, Lemonnier FA, et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A 2003; 100:217 - 22; http://dx.doi.org/10.1073/pnas.262668999; PMID: 12518065
   PubMed Web of Science ®Google Scholar